KLK3 and pachyonychia congenita: In developed countries, incidence is higher, possibly due to greater availability of prostate-specific antigen (PSA) testing [2, 3], and despite a significant mortality decrease (52% since 1993), PC remains the second cause of cancer-related death [2].